Invivyd Q3 Pemgarda revenue reaches $15.4M as VYD2311 data timing shifts after FDA talks
Invivyd reports $15.4 million in third-quarter Pemgarda net revenue and $126.4 million in cash, while Phase 3 DECLARATION data for VYD2311 are now timed differently following FDA discussions.
Invivyd reported third-quarter 2026 results on 16 November, citing net revenue of $15.4 million for Pemgarda (pemivibart), its COVID-19 antibody. The headline on the company's announcement put the increase at 18%. The company held $126.4 million in cash at the end of the period.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Invivyd, Inc. ↗
Article written by VigiEye from the official source (Invivyd, Inc.). Claims are the company's own. AI-assisted; check the source before acting.